Ch’ang HJ. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol 2015; 7(16): 2029-2040 [PMID: 26261692 DOI: 10.4254/wjh.v7.i16.2029]
Corresponding Author of This Article
Hui-Ju Ch’ang, MD, National Institute of Cancer Research, National Health Research Institutes, R1-2034, 35, Keyen Road, Miaoli 35053, Taiwan. hjmc@nhri.org.tw
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Aug 8, 2015; 7(16): 2029-2040 Published online Aug 8, 2015. doi: 10.4254/wjh.v7.i16.2029
Optimal combination of antiangiogenic therapy for hepatocellular carcinoma
Hui-Ju Ch’ang
Hui-Ju Ch’ang, National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan
Hui-Ju Ch’ang, Department of Radiation Oncology, Taipei Medical University Hospital, Taipei 100, Taiwan
Author contributions: Ch’ang HJ solely contributed to this manuscript.
Supported by National Health Research Institutes, Taiwan.
Conflict-of-interest statement: Nothing to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hui-Ju Ch’ang, MD, National Institute of Cancer Research, National Health Research Institutes, R1-2034, 35, Keyen Road, Miaoli 35053, Taiwan. hjmc@nhri.org.tw
Received: July 29, 2014 Peer-review started: July 30, 2014 First decision: December 17, 2014 Revised: July 21, 2015 Accepted: July 24, 2015 Article in press: July 27, 2015 Published online: August 8, 2015
Core Tip
Core tip: Antiangiogenic therapy has become an important component of treatment in hepatocellular carcinoma (HCC) patients. However, traditional anatomic imaging of tumor shrinkage is not appropriate to evaluate the efficacy of antiangiogenesis achieved by normalizing tumor vasculature and systemic suppression of angiogenic and inflammatory cytokines. To identify and validate potential response biomarkers, standardized systemic, circulating, tissue and imaging assays should be incorporated in to preclinical and clinical studies regarding the combination of antiangiogenic agents to cytotoxic or biologic agents. The optimal dosage, schedule and duration of antiangiogenic during combination therapy for HCC patients should be titrated according to these response biomarkers.
